Tower Research Capital (TRC)’s Actuate Therapeutics ACTU Stock Holding History

Tower Research Capital (TRC)’s Portfolio ACTU Stock Details ACTU Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$5.56K	Sell	3,634 -2,120	-37%	-$4.91K	﹤0.01%	4270
2026 Q1	$15.8K	Buy	5,754 +4,118	+252%	+$17.1K	﹤0.01%	3652
2025 Q4	$10K	Sell	1,636 -7	-0.4%	-$48	﹤0.01%	3848
2025 Q3	$11K	Buy	1,643 +1,630	+12,538%	+$11.8K	﹤0.01%	3928
2025 Q2	$79	Sell	13 -2,542	-99%	-$22.2K	﹤0.01%	5165
2025 Q1	$17.3K	Buy	+2,555	New	+$20.5K	﹤0.01%	3111
2024 Q4	–	Sell	-297	Closed	-$2.21K	–	6084
2024 Q3	$2.21K	Buy	+297	New	+$2.35K	﹤0.01%	5029

Other funds holding ACTU

BCM

BIOS Capital Management Fort Worth, Texas $41.7M AUM 34.92% 1-Year Est. Return

Voss Capital Houston, Texas $2.15B AUM 33.46% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

TCBWMS

Texas Capital Bank Wealth Management Services Dallas, Texas $1.87B AUM 24.49% 1-Year Est. Return

PVM

Palogic Value Management Dallas, Texas $304M AUM 15.15% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ADEF

ABS Direct Equity Fund Stamford, Connecticut $159M AUM 34.17% 1-Year Est. Return

Tower Research Capital (TRC)'s ACTU Position: Q2 2026 in Review

Tower Research Capital (TRC) reduced its Actuate Therapeutics (ACTU) stake by 37% in Q2 2026, selling an estimated $4.91K and leaving 3,634 shares worth $5.56K. The position accounts for ﹤0.01% of the portfolio, ranked #4270.

Tower Research Capital (TRC) first reported a position in ACTU in Q3 2024 and has held it in 7 quarters since. The position peaked at $17.3K in Q1 2025. 64 funds tracked by Wall St. Rank hold ACTU as of Q2 2026.

Tower Research Capital (TRC) held 3,634 shares of Actuate Therapeutics worth $5.56K as of Q2 2026.
Tower Research Capital (TRC) sold 2,120 Actuate Therapeutics shares in Q2 2026, an estimated $4.91K.
Actuate Therapeutics made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #4270 holding.
Tower Research Capital (TRC) first reported a position in Actuate Therapeutics in Q3 2024 and has held it in 7 quarters since.
Tower Research Capital (TRC)'s Actuate Therapeutics position peaked at $17.3K in Q1 2025.
64 funds tracked by Wall St. Rank held Actuate Therapeutics as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.